Filters close
Newswise: Sylvester Surgical Oncologist Awarded $375,000 NCI Grant to Investigate the Role Opioids May Play in Breast Cancer
Released: 28-Mar-2023 3:50 PM EDT
Sylvester Surgical Oncologist Awarded $375,000 NCI Grant to Investigate the Role Opioids May Play in Breast Cancer
Sylvester Comprehensive Cancer Center

Kristin Rojas, M.D., assistant professor of surgical oncology at Sylvester Comprehensive Cancer Center, has been awarded a three-year, $375,000 grant to investigate the role opioids may play in breast cancer.

Newswise: March Tip Sheet From Sylvester Comprehensive Cancer Center
Released: 24-Mar-2023 4:00 PM EDT
March Tip Sheet From Sylvester Comprehensive Cancer Center
Sylvester Comprehensive Cancer Center

A new study reported in JAMA Network Open unveils disparities in Mesothelioma survival, a grant to help construction workers nail quitting smoking, a new AI algorithm that offers insights into deadly cancer, a newly launched Neuroendocrine Tumors Program, a cancer researcher chosen to co-lead Tumor Biology Program and more are in this month’s tip sheet from Sylvester Comprehensive Cancer Center.

Newswise: Sylvester Cancer Investigators Find Disparities in Mesothelioma Survival Due to Social Determinants, Limited Access
22-Mar-2023 6:40 PM EDT
Sylvester Cancer Investigators Find Disparities in Mesothelioma Survival Due to Social Determinants, Limited Access
PR Pacific

Treatment outcomes for patients with malignant pleural mesothelioma, a rare cancer commonly known as mesothelioma, are often affected by social determinants of health and overall survival rates could be improved by addressing these health disparities and improving access to specialized care.

Released: 23-Jan-2023 5:05 PM EST
Coordination of COVID-19 Vaccine Clinical Trials Produces a ‘Treasure Trove’ of Data and a Model for the Future
Covid-19 Prevention Network (CoVPN)

The federally funded COVID-19 Prevention Network was instrumental in the rapid development of safe, effective and lifesaving COVID-19 vaccines during earlier phases of the pandemic. This vital work to expedite Phase 3 clinical trials also resulted in a 'treasure trove' of data, thanks to a highly collaborative and harmonized approach that can serve as a national and even international model for major research initiatives while also guiding responses to future public health emergencies.

Released: 18-Jan-2023 10:00 AM EST
Phase 3 Mosaic-Based Investigational HIV Vaccine Study Discontinued Following Disappointing Results of Planned Data Review
HIV Vaccine Trials Network

A Phase 3 study of an investigational HIV vaccine regimen has been discontinued following a planned, interim review by the study’s independent Data and Safety Monitoring Board. The investigational vaccine was generally safe and well tolerated; however, it was not effective at preventing the acquisition of HIV-1. The results of the uniquely designed and implemented Mosaico study underscore the challenges that have faced the global scientific community in the 40-year search for an HIV vaccine, and may provide important data in the ongoing fight against HIV.

Released: 11-Oct-2022 6:30 PM EDT
The NIH/DAIDS Cross-Network (ACTG/HVTN/IMPAACT) TB Vaccine Working Group calls for people living with HIV to be included in tuberculosis vaccine development
HIV Vaccine Trials Network

People living with HIV must be included in clinical trials for new tuberculosis vaccine candidates currently in the development pipeline, say experts on an international panel convened last year to address gaps in the current TB vaccine landscape. Their recommendations appear in a new paper published today in The Lancet HIV.

16-Aug-2022 3:50 PM EDT
Additional Antibody Mediated Prevention (AMP) trials data published in Nature Medicine
HIV Vaccine Trials Network

An embargoed study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS. Broadly neutralizing antibodies (bnAbs) are defined by their ability to neutralize multiple genetically distinct viral strains.

28-Jul-2022 10:00 AM EDT
HVTN at the 24th International AIDS Conference in Montreal
HIV Vaccine Trials Network

Scientists, doctors and other health professionals from the HIV Vaccine Trials Network (HVTN) will present research findings and other HIV-related news at AIDS 2022, the International AIDS Conference taking place virtually and in person in Montreal, Canada, July 29 to Aug. 2.

Released: 28-Jun-2022 11:05 AM EDT
CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2
Covid-19 Prevention Network (CoVPN)

A new analysis of the Novavax PREVENT-19 clinical trial concluded that this recombinant protein vaccine produced an antibody response comparable to mRNA vaccines and, if authorized, could help bolster global vaccine supplies. This is the first study to directly support antibody correlates of protection for a recombinant protein COVID-19 vaccine.

Newswise: After Sprint for COVID-19 Vaccines, HVTN Researchers Return to HIV Marathon With Fresh Determination and Knowledge, Launch Clinical Research Registry and Ad Campaign
Released: 18-May-2022 9:55 AM EDT
After Sprint for COVID-19 Vaccines, HVTN Researchers Return to HIV Marathon With Fresh Determination and Knowledge, Launch Clinical Research Registry and Ad Campaign
HIV Vaccine Trials Network

SEATTLE (May 18, 2022) – Building on momentum from the highly successful COVID-19 vaccine clinical trials, the HIV Vaccine Trials Network (HVTN) is launching a new HIV awareness campaign and unveiling a first-of-its-kind national registry that will provide updated HIV information and make it easier to learn about and participate in HIV clinical trials at

Released: 15-Mar-2022 7:05 PM EDT
Increased support needed for a coordinated global HIV and COVID-19 response
HIV Vaccine Trials Network

In a JAMA perspective piece, leading infectious disease researchers call for a coordinated response to HIV and COVID-19 globally, building on the successes of key donor programs such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program and Global Fund to Fight AIDS, TB and Malaria (GFATM).

Released: 14-Mar-2022 9:00 AM EDT
Trial of innovative HIV vaccine using mRNA technology enrolls first participant
HIV Vaccine Trials Network

The first 12 study participants have been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid (mRNA) vaccine technology developed by Moderna. The study evaluates the safety of and immune responses to three different experimental vaccines against HIV. This randomized, open-label trial represents one of the first clinical studies of the use of mRNA vaccine technology against HIV.

Released: 7-Jan-2022 8:00 AM EST
Preliminary findings from studies in South Africa indicate that omicron has a much higher rate of asymptomatic ‘carriage’ than other variants of concern
Covid-19 Prevention Network (CoVPN)

Preliminary findings from two clinical trials in South Africa suggest that the omicron variant of the virus that causes COVID-19 may have a much higher rate of asymptomatic ‘carriage’ than earlier variants. This higher asymptomatic carriage rate is likely a major factor in the rapid and widespread dissemination of the variant, even among populations with high prior rates of coronavirus infection.

Released: 14-Dec-2021 8:05 PM EST
HVTN Faith Initiative expands to help build bridges between community and HIV vaccine trials
HIV Vaccine Trials Network

While the rapid development of effective vaccines has helped combat the COVID-19 pandemic, key communities – especially people who are living with HIV – remain disproportionately impacted, and are at higher risk of severe disease and death. Finding an effective HIV vaccine is critically important, and to that end, the HIV Vaccine Trials Network (HVTN) is launching an expanded Faith Initiative that will help advance the work of finding a cure.

Released: 13-Dec-2021 1:25 PM EST
Landmark COVID-19 vaccine trial in sub-Saharan Africa is the first to study the efficacy of mRNA COVID-19 vaccines in people living with HIV
Covid-19 Prevention Network (CoVPN)

A highly anticipated clinical trial in eight sub-Saharan countries is the first to specifically evaluate the efficacy of a COVID-19 vaccine in people living with HIV, including those with poorly controlled infections. It also is the first study to evaluate the efficacy of vaccines – in this case, Moderna mRNA-1273 – against the omicron variant of SARS-CoV-2, the virus that causes COVID-19.

Released: 19-Oct-2021 4:35 PM EDT
New study demonstrates community engagement efforts are critical to ensuring the equitable inclusion of BIPOC communities in vaccine clinical trials
Covid-19 Prevention Network (CoVPN)

A team of research experts from the COVID-19 Prevention Network (CoVPN), headquartered at Fred Hutchinson Cancer Research Center, has demonstrated that through robust community engagement, equitable inclusion in vaccine clinical trials can make a powerful impact in the health of underrepresented communities.

Released: 25-Aug-2021 4:50 PM EDT
NeuroVision Imaging Inc. Announces Additional Funding From the ADDF to Accelerate Development of Novel Blood-Based Lab Test to Predict Dementia Before Clinical Onset

NeuroVision Imaging Inc. has received an additional investment from the Alzheimer’s Drug Discovery Foundation to hasten development of a novel blood-based lab test to provide detection and measurement of biomarkers for Alzheimer’s disease and other dementias before clinical onset.

22-Jun-2021 12:00 PM EDT
Study Testing How Well COVID-19 Vaccine Prevents Infection and Spread of SARS-CoV-2 Among University Students Now Expands to Include Young Adults Beyond the University Setting
Covid-19 Prevention Network (CoVPN)

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

Released: 26-Mar-2021 11:30 AM EDT
New clinical trial will test if COVID-19 vaccine prevents infection and spread of SARS-CoV-2 among college students
Covid-19 Prevention Network (CoVPN)

A new CoVPN study evaluating SARS-CoV-2 infection and transmission among college students vaccinated with the Moderna COVID-19 vaccine was announced today. The new trial will tell us whether a person can become infected after they’ve been vaccinated and if the vaccine will stop the virus from spreading person-to-person.

Released: 18-Mar-2021 9:00 AM EDT
Antibody Mediated Prevention (AMP) trials data published by the New England Journal of Medicine
HIV Vaccine Trials Network

The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains to the 30% of strains that were sensitive to the bnAb. This finding was seen both in Sub-Saharan Africa and the U.S. and South America. VRCO1 did not prevent the acquisition of HIV to strains that were resistant to the bNAb.

Released: 11-Mar-2021 8:05 AM EST
CoVPN’s Faith and Diversity Work Engages Key Communities Impacted by COVID-19
Covid-19 Prevention Network (CoVPN)

The COVID-19 Prevention Network (CoVPN) released today the CoVPN Faith Initiative and Diversity Report, which provides a snapshot of key work to build trust, inform and engage the communities hardest hit by the pandemic in conversations about faith, COVID-19 and CoVPN clinical trials.

Released: 2-Feb-2021 5:50 PM EST
NeuroVision Imaging Inc., Announces New Funding From the ADDF to Develop Affordable, Accessible Biomarkers to Diagnose Alzheimer’s and Related Dementias

NeuroVision Imaging Inc., announced today it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders.

Released: 10-Sep-2020 8:30 AM EDT
New National Faith-Based Community Engagement Initiative to Partner with Key Communities Around COVID-19 and CoVPN Clinical Trials
PR Pacific

With many communities across the U.S. disproportionately impacted by the COVID-19 pandemic, the recently formed COVID-19 Prevention Network (CoVPN), has established a national, faith-based program called the CoVPN Faith Initiative to enhance trust and meaningful engagement in key communities and provide accurate and updated information about COVID-19 and CoVPN clinical trials.

Released: 18-Jul-2018 12:00 PM EDT
Alzheimer’s Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Board

Roy Ervin Twyman, MD, PhD, an academic neurologist with nearly 20 years’ experience in neuroscience pharmaceutical drug development, will join the NeuroVision Imaging Inc. Board of Directors on July 20.

Released: 2-May-2018 6:00 AM EDT
NeuroVision Announces a $15 Million Series C Financing with a first close of $11.2 Million

NeuroVision Imaging Inc. has announced a Series C financing round of $15 million with an initial close of $11.2 million. The round is led by Wildcat Capital Management with funding from several new investment groups. The financing provides support for NeuroVision as it seeks validation and regulatory approval for its breakthrough, low-cost, noninvasive, eye imaging system for measuring retinal autofluorescence that can detect amyloid beta (Aβ) plaque in the eye.

Released: 22-Aug-2017 8:55 AM EDT
Clinical Study Shows That Retinal Imaging May Detect Signs of Alzheimer’s Disease
PR Pacific

A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer’s. The experimental technology, developed by Cedars-Sinai and NeuroVision, scans the retina using techniques that can identify beta-amyloid protein deposits that mirror those in the brain.

Released: 27-Feb-2017 5:05 PM EST
NeuroVision Announces Participation in Landmark Alzheimer’s A4 Study Evaluating Its Novel Retinal Imaging Technology
PR Pacific

NeuroVision Imaging LLC (“NeuroVision”) today announced its participation in a new substudy with investigators at the University of California San Diego School of Medicine (UC San Diego) and the University of Southern California (USC) to be part of the landmark Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (or “A4”) clinical trial. The purpose of the A4 study is to test whether a new investigational treatment that may reduce beta-amyloid accumulation in the brain can also slow memory loss caused by Alzheimer’s disease.

Released: 5-May-2016 6:05 PM EDT
RAND/Harvard Study Shows Teledermatology Increases Patient Access to Specialized Skin Care
PR Pacific

Offering virtual dermatology care significantly improved access to specialized skin care for a group of patients that traditionally has limited options, according to an independent study led by researchers at the RAND Corporation and Harvard Medical School’s Department of Health. The findings appear in a JAMA Dermatology article published online May 4.

Released: 12-May-2015 8:05 PM EDT
Roger Daltrey Announces New National Ambassadors For Teen Cancer America: The Band Perry
PR Pacific

Roger Daltrey, a passionate advocate for teens and young adults with cancer, announced Monday that Kimberly, Reid and Neil Perry of the Grammy Award-winning trio The Band Perry will serve as one of Teen Cancer America’s national ambassadors. The announcement was made in a press conference prior to The Who’s Nashville show at the Bridgestone Arena.

Released: 27-Jan-2010 2:40 PM EST
Keith Black Named Recipient of 2010 BET Honors Award for Public Service and Nominated for 41st NAACP Image Award
PR Pacific

Keith L. Black, M.D., has been named the recipient of the 2010 BET Honors Award in Public Service. In addition, he has been nominated for an NAACP Image Award in the Outstanding Literary Work/Non-fiction category for his book, “BRAIN SURGEON: A Doctor’s Inspiring Encounters with Mortality and Miracles.”

Released: 24-Jun-2008 9:00 AM EDT
Big Babies: Healthy Twins with Combined Weight of 23 lbs. 1 oz. Delivered
Sara Lee Center for Women's Health at Forsyth Medical Center

Boy and girl believed to have heaviest combined birth weight ever recorded in North Carolina and second highest in the United States during the last century.

Released: 22-Mar-2006 1:00 PM EST
A “Sandwich Generation” Mom Enjoys Renewed Optimism
PR Pacific

Life is finally looking up for Timona Bridges. The Los Angeles resident and mother of three joined the "sandwich generation" at an early age"”just 33"”and it was a role increasingly hard to manage. Until just recently, that is, when WISE Senior Services stepped in to lighten the load.

Showing results 1 – 32 of 32